Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanober Malik

Internal Medicine Norman, OK Medical Doctor

NPI 1891835708 CMS profile 312838

3400 W Tecumseh Rd, Suite 202, Norman, OK 73072

Open in the dashboard

General payments

$9,165

473 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanober Malik of Norman, OK is reported in the CMS Open Payments database as having received $9,165 across 473 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,931 85
2024 General $1,722 81
2023 General $1,692 80
2022 General $1,553 82
2021 General $997 55
2020 General $312 20
2019 General $957 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanober Malik
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sanober Malik were reported at $1,931. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sanober Malik Internal Medicine median Middle half National median
2019 $957 $159 $48–$570 $163
2020 $312 $119 $33–$402 $114
2021 $997 $135 $37–$521 $132
2022 $1,553 $141 $42–$496 $149
2023 $1,692 $149 $45–$519 $160
2024 $1,722 $154 $47–$537 $164
2025 $1,931 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,478 89 payments
  2. AstraZeneca Pharmaceuticals LP $1,039 49 payments
  3. AbbVie, Inc. $957 53 payments
  4. Novartis Pharmaceuticals Corporation $654 30 payments
  5. Lilly USA, LLC $584 30 payments
  6. UCB, Inc. $562 30 payments
  7. GlaxoSmithKline, LLC. $456 27 payments
  8. E.R. Squibb & Sons, L.L.C. $432 24 payments
  9. Janssen Biotech, Inc. $423 15 payments
  10. Actelion Pharmaceuticals US, Inc. $399 18 payments
  11. Other $2,182 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,984 470 payments
  2. Education $180 3 payments
Products named General payments · program years 2019–2025
  1. SAPHNELO $1,039 49 payments
  2. RINVOQ $670 37 payments
  3. TALTZ $584 30 payments
  4. COSENTYX $575 26 payments
  5. Otezla $476 22 payments
  6. Enbrel $460 22 payments
  7. BENLYSTA $439 26 payments
  8. ORENCIA $409 23 payments
  9. OPSUMIT $399 18 payments
  10. Cimzia $369 22 payments
  11. Other $5,458 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

3,373

Median for Rheumatology: 1,511

Drug cost

$4,912,693

Median for Rheumatology: $1,139,948

Branded share of claims

32.6%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 172 $1,382,492
Humira(Cf) Pen Adalimumab Brand 146 $1,092,301
Orencia Clickject Abatacept Brand 66 $444,390
Actemra Actpen Tocilizumab Brand 59 $253,447
Kevzara Sarilumab Brand 45 $250,866
Benlysta Belimumab Brand 49 $247,806
Xeljanz Tofacitinib Citrate Brand 40 $225,200
Rinvoq Upadacitinib Brand 29 $219,502
Humira(Cf) Adalimumab Brand 29 $199,511
Humira Pen Adalimumab Brand 24 $161,125

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$122,436

Of which drugs: $101

Medicare patients

506

Average age 72

Services billed

2,435

419 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 34%
Ischemic heart disease 31%
Depression 31%
Diabetes 29%
Chronic kidney disease 23%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $256
$256 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $233
$233 11 —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $152
$152 66 —
Enbrel
  • Amgen Inc. $111
$111 172 —
KRYSTEXXA
  • Amgen Inc. $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record